The low bioavailability of most flavonoids limits their application as anti-carcinogenic agents in humans. A novel approach of treatment with a mixture of bioactive compounds that share molecular anti-carcinogenic targets may enhance the effect on these targets at low concentrations of individual compound, thereby overcoming the limitations of reduced bioavailability. We therefore investigated whether a combination of three natural products arctigenin (Arc), a novel anti-inflammatory lignan from the seeds of Arctium lappa, green tea polyphenol (-)-epigallocatechin gallate (EGCG) and curcumin 
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Introduction
Prostate and breast cancers are the most frequently diagnosed malignancy in men and women in the United States, and both are the second leading cause of cancer death by gender 1 . Both cancers are typically diagnosed at a later age and subject to dietary factors and obesity [2] [3] [4] , which makes them good candidates for chemoprevention to delay or suppress their development. Increasing evidence from preclinical studies is demonstrating that bioactive products may be a non-toxic alternative in prevention and treatment of chronic diseases including cancer 5, 6 . However, translation of these results to clinical studies is limited, mainly due to the low bioavailability of these compounds and their extensive biotransformation in vivo into less active metabolites 5, 6 . To overcome these limitations mixtures of bioactive compounds, as traditionally used in Chinese and Indian/Ayurvedic medicine, may be employed. Many bioactive compounds share the same molecular anticarcinogenic targets. Therefore, the sum activity of combination treatment with several bioactive compounds may enhance the effect on their molecular targets at low concentrations of individual compound.
Curcumin (structure shown in Figure 1A ) is a hydrophobic polyphenol derived from the root of the plant Curcuma longa (commonly known as turmeric). The commercial curcumin products usually contain curcuminoids including curcumin (77%), demethoxycurcumin (17%), and bisdemethoxycurcumin (3%).
The chemopreventive activity of curcumin has been well demonstrated in vitro and in animal models against most cancers such as colorectal, pancreatic, liver, lung, prostate and breast cancer 7 . Curcumin targets multiple molecules and signaling pathways involved in carcinogenesis, including the nuclear factor kappa B (NFκB), signal transducer and activator of transcription (Stat) 3 and phosphatidylinositide 3-kinases (PI3K)/Akt pathways, epidermal growth factor (EGF) and its receptor (EGFR), and angiogenesis 7 . A number of clinical trials with curcumin have been completed, and the majority supports a cancer preventive potential of curcumin 7, 8 . However, the efficacy of curcumin is limited by its poor bioavailability. Biologically effective levels of curcumin may be only achievable in the gastrointestinal tract while not in other parts of the body by oral consumption 9 . Less than 2 µM of curcumin was detected in human serum after oral uptake of 8g of curcumin 8 , while no curcumin was detectable in liver tumor tissues from patients with hepatic metastases from colorectal cancer after consumption of 3.6g of curcumin for one week prior to surgery 10 .
A combination treatment of green tea (GT) with curcumin has demonstrated a synergistic effect in inhibition of oral epithelial and breast cancer cell growth 11, 12 . GT is produced from the leaves of the plant Camellia sinensis. The major bioactive components of GT are GT polyphenols (GTPs, structures in Figure 1B ) including (-)-epigallocatechin, (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin, and (-)-epicatechin-3-gallate, with EGCG being the major component 13 . GT targets multiple signaling pathways in anti-carcinogenesis, and the chemopreventive effect of GT has been demonstrated in several cancers including prostate and breast cancer 5, 6, 14 . A previous study showed that the combination of 20-25µM EGCG and 2-3µM curcumin synergistically increased the anti-proliferative effect in cultured breast cancer MDA-MB-231 cells, and the combined effect was further confirmed in vivo in the inhibition of MDA-MB-231 xenograft tumor growth in athymic nude mice 12 .
In a screening of 15 commonly studied anti-carcinogenic natural compounds, we found that arctigenin synergistically enhanced the anti-proliferative effect of both curcumin and EGCG in prostate cancer
LNCaP cells. Therefore it may be an ideal candidate to further enhance the efficacy of curcumin plus GT combination. Arctigenin (structure in Figure 1C ) is a lignan derived mainly from the seeds of the plant Arctium lappa which is widely used in traditional Chinese medicine to treat inflammation related diseases such as cough, cold and swelling of throat 15 . In the plant arctigenin is present as glucoside (arctiin) and arctigenin is released during the digestive process 16 . Both have been detected in rat plasma after oral administration of arctiin 16 . Arctigenin has exhibited multiple activities including the antioxidant, antiproliferative and anti-inflammatory activities 15, 17 . The anti-carcinogenic property of arctigenin has been demonstrated in several cancers including pancreatic and colorectal cancer 17, 18 . The present study investigated the combined effect of the three chemicals, arctigenin, EGCG and curcumin, in prostate cancer LNCaP and breast cancer MCF-7 cells. This study is expected to provide a novel nontoxic formulation to enhance the chemoprevention in prostate and breast cancer particularly for those high-risk populations.
Materials and Methods

Cell line and cell culture
The 
Cell proliferation assay
Both LNCaP and MCF-7 cells were seeded into 96-well plates at a density of 8x10 3 In addition, a combination index (CI) was calculated for the mixture of all three chemicals using the CompuSyn software (ComboSyn, Inc., Paramus, NJ) which is based on the widely-accepted ChouTalalay equation and mass-action law 20 . The value of CI less than 1 indicates a synergistic effect of a combination, equal to 1 additive, and greater than 1 antagonistic 20 .
Cell cycle and apoptosis analysis using Cellometer imaging cytometry
LNCaP and MCF-7 cells were cultured in T25 flasks. When 50-60% confluent both cell lines were treated with vehicle control, 40μM
EGCG, 2mg/L curcumin + 1μM arctigenin, or 2mg/L curcumin + 40μM EGCG + 1μM arctigenin for 48h. Cells were trypsinized and monolayers attaching to the bottom were collected. The procedures for cell cycle and apoptosis analysis using a small cytometry system Cellometer Vision (Nexcelom Bioscience LLC, Lawrence, MA) were described previously 21, 22 . Results obtained from this system have been shown to be comparable to that from conventional flow cytometry 21, 22 . The procedures were modified slightly in the present study. Briefly, for cell cycle assay cells were centrifuged at 2,000 rpm for 5min and the pellet containing 2x10 6 The results were also confirmed by flow cytometry at the UCLA Janis V. Giorgi cytometry core facility.
Western blot analysis of protein biomarkers
When 50-60% confluent in 60 mm Petri dishes, both LNCaP and MCF-7 cells were treated with vehicle 
Migration assay
The capacity of these compounds and their combinations to inhibit cell migration was tested in MCF-7 cells using both transwell chamber and scratch assays. counted under a microscope at x200 magnification. Three fields for each wells were counted and the experiment was done in triplicate.
Scratch wound assay
MCF-7 cells were cultured in 24-well plate to 90-100% confluency. Cells were starved in serum-free medium overnight. A line was drawn with a marker pen on the bottom of the plate across the middle of 
Results
Enhanced antiproliferative effect by combination treatment
The IC 50 values of curcumin, EGCG and arctigenin in LNCaP cells were 12.5µM, 130µM and 13µM, respectively, and 30µM, 100µM and 16µM in MCF-7 cells. The combination treatment increased the antiproliferative effect in both LNCaP cells and MCF-7 cells compared to individual treatment ( Figure   2 ). LNCaP cell growth was inhibited by 11% (EGCG), 29% (arctigenin), 22% (LD curcumin), 34% (LD curcumin+EGCG), 49% (LD curcumin+arctigenin), and 62% (LD curcumin+EGCG+ arctigenin) compared to control. The combined effect was further enhanced by increasing curcumin concentration (HD), and LNCaP cell growth was inhibited by 75% by the combination of all three chemicals ( Figure   2 ). Overall, arctigenin and EGCG increased the antiproliferative effect of curcumin by 40% in both 
Effect on apoptosis and cell cycle distribution
The individual treatment with curcumin, EGCG or arctigenin significantly increased cell apoptosis in LNCaP cells compared to control, and the effect was further enhanced by the combination of either EGCG or arctigenin with curcumin with the strongest effect by combining all three compounds (Table   1) . Similarly, all the three compounds induced cell apoptosis in MCF-7 cells when used alone. However, only arctigenin enhanced the pro-apoptotic effect of curcumin (Table 2 ). EGCG significantly increased the effect of curcumin on cell cycle arrest at G0/G1 phase in MCF-7 cells, and the effect was further enhanced by the addition of arctigenin (Table 2 ).
Modulation on protein markers of apoptosis and cell proliferation
We examined the effect of these compounds particularly their combinations on several important signaling pathways involved in cell apoptosis and proliferation. An increased ratio of Bax to Bcl-2 proteins was observed by individual treatment of curcumin, EGCG and arctigenin in LNCaP cells (Figure 3) , and by arctigenin in MCF-7 cells (Figure 4) . The ratio was significantly increased by combination treatment and the highest ratio was achieved with the mixture of all three compounds in both LNCaP and MCF-7 cells (Figures 3 & 4) . The phosphorylation of NFκB was increasingly inhibited by the combination treatment along with decreased p-IκB levels in both cell lines (Figures 3 & 4) . In addition, the three chemicals in combination significantly decreased the phosphorylation of Akt and Stat3 compared to individual treatment (Figures 3 & 4) .
Inhibition of cell migration
In the transwell chamber assay, both EGCG and arctigenin alone or in combination with curcumin significantly decreased the number of migrated MCF-7 cells compared to control ( Figure 5A ). The effect was further enhanced by combining all three compounds, leading to a 20% inhibition of cell migration compared to control ( Figure 5A ). The same pattern was observed in the scratch assay. All the treatments significantly inhibited the closure of wounds compared to control, and the combination of the three chemicals demonstrated a trend to increase the inhibitory effect ( Figure 5B ). At 48h, the wound was closed by 71% (control), 40% (40μM EGCG), 42% (1μM arctigenin), 40% (2mg/L curcumin), 41% (2mg/L curcumin + 40μM EGCG), 36% (2mg/L curcumin + 1μM arctigenin), and 28% (2mg/L curcumin + 40μM EGCG + 1μM arctigenin).
Discussion
The major finding of this study is that although all three phytochemicals have similar molecular targets and mode of action, a mixture of curcumin, EGCG and arctigenin synergistically enhanced the antiproliferative effect in both prostate and breast cancer cells. In the combination treatment low concentrations were effective, which when used alone induced minor changes in proliferation. The enhanced anti-proliferative effect by combination of Arc with curcumin and EGCG was associated with increased apoptosis and cell cycle arrest, through an enhanced modulation of multiple important signaling pathways involved in carcinogenesis including the PI3K/Akt and NFκB pathways. Natural products are a major source for development of non-toxic chemopreventive agents. However, the low bioavailability of these compounds hinders their application in humans, and effective doses as 
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cancer, and both pathways have been proved to be effective targets in cancer prevention and treatment [32] [33] [34] . Extracellular stimuli such as tumor necrosis factor (TNF)-α, can stimulate the phosphorylation and dissociation of NFκB inhibitor protein IκB. Once released, NFκB is activated by phosphorylation and migrates to the nucleus to initiate the transcription of many genes promoting cell growth and suppressing apoptosis 32, 33 . The PI3K/Akt pathway is another important pathway involved in carcinogenesis 34 . Once Akt is activated by phosphorylation it regulates multiple target genes leading to increased cell proliferation and survival 35 . In addition, PI3K/Akt pathway may cross-activate the NFκB pathway 34 . Among the three chemicals in this study, arctigenin demonstrated the strongest ability to inhibit the activation of both PI3K/Akt and NFκB pathways in both LNCaP and MCF-7 cells. The inhibitory effect of arctigenin on these two pathways was also reported by other investigators, which was found associated with reduced production of nitric oxide synthase and TNF-α 18, 36, 37 . An increased inhibition on both pathways was achieved by the combination of arctigenin with curcumin and EGCG, which may be due to a sum of the activities on these molecular targets by the three chemicals.
In addition, an inhibitory effect on the signal transducer and activator of transcription (Stat) pathway was observed with all three chemicals, which supports findings from other investigators [38] [39] [40] . The activities of the transcription factor Stat, particularly the members Stat3 and Stat5, have been shown to be required to sustain a transformed phenotype, and they represent suitable targets for cancer therapy 41 .
Stat3 is phosphorylated in response to cytokines and growth factors, and enters the nucleus to mediate the expression of various genes in regulation of cell growth, survival and motility 41 . A recent study
showed that the inhibition of Stat3 protein expression and activation by EGCG significantly inhibited cell motility, migration and invasion, and increased apoptosis in human pancreatic cancer cells 38 . The increased inhibition of Stat3 pathway by the mixture of the three chemicals in our study may in part explain the increased inhibition of cell migration in MCF-7 cells. 
Conclusions
In summary, the combination of three bioactive phytochemicals, curcumin, EGCG and arctigenin, synergistically enhanced the anti-proliferative effect in both prostate and breast cancer cells. The combined effect was associated with increased modulations on several important signaling pathways involved in carcinogenesis. These results warrant future animal studies and clinical trials to confirm the combined effect of this novel regimen in vivo. 
